1. Home
  2. VABK vs ADAG Comparison

VABK vs ADAG Comparison

Compare VABK & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virginia National Bankshares Corporation

VABK

Virginia National Bankshares Corporation

HOLD

Current Price

$45.50

Market Cap

235.8M

Sector

Finance

ML Signal

HOLD

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$3.59

Market Cap

260.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VABK
ADAG
Founded
1998
2011
Country
United States
China
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
235.8M
260.3M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
VABK
ADAG
Price
$45.50
$3.59
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.25
AVG Volume (30 Days)
7.2K
353.4K
Earning Date
04-23-2026
04-01-2026
Dividend Yield
3.39%
N/A
EPS Growth
12.70
N/A
EPS
0.97
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$47.23
N/A
Revenue Growth
N/A
N/A
52 Week Low
$36.60
$1.44
52 Week High
$48.58
$4.85

Technical Indicators

Market Signals
Indicator
VABK
ADAG
Relative Strength Index (RSI) 69.87 42.97
Support Level $38.18 $3.21
Resistance Level $48.18 $4.09
Average True Range (ATR) 1.05 0.43
MACD 0.21 -0.08
Stochastic Oscillator 100.00 3.79

Price Performance

Historical Comparison
VABK
ADAG

About VABK Virginia National Bankshares Corporation

Virginia National Bankshares Corp is a bank holding company engaged in commercial and retail banking. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts, and other depository services. Its segments include the Bank, VNB Trust and Estate Services, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits, and offering related services to individuals, businesses, and charitable organizations.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: